Company file · MEDP
Medpace
Metabolic was Medpace's fastest-growing product or service in FY2025, up 62.8%
Revenue rose 20.0% to $2.5B in FY2025, from $2.1B in FY2024. Net income rose 11.6% to $451M. Oncology was the largest product or service, at 30% of revenue.
Key facts
Medpace (Nasdaq: MEDP) reported revenue of $2.5B for fiscal 2025, the year ended Dec 31, 2025, up 20.0% from fiscal 2024. Net income was $451M, up 11.6%. In its latest 10-Q, for the quarter ended Sep 30, 2026, revenue was $716M, up 8.5% from the same quarter a year earlier, and net income was $137M. The largest piece by product or service was Oncology, at 30% of fiscal 2025 revenue. Sources: 10-K for fiscal 2025 (filed Feb 10, 2026) and 10-Q for the quarter ended Sep 30, 2026 (filed Oct 22, 2026).
Source: 10-K FY2025, filed Feb 10, 2026
Source: 10-Q filed Apr 23, 2026 · 10-Q filed Jul 23, 2026 · 10-Q filed Oct 22, 2026
How it makes money
By product or service in FY2025: Oncology (30%), Metabolic (29%), Other (16%) and Central Nervous System (10%), as shares of total revenue. Total revenue was $2.5B.
Source: 10-K FY2025
Learn more: Revenue vs. net income · Gross, operating and net margin
What changed last quarter
Comparing Q3 2026 (Jul to Sep 2026) compared with Q3 2025 (Jul to Sep 2025)
Each pair of bars shows the dollar amount for both quarters. Longer bar, more money. Bars in a group share one scale.
Q3 2026Q3 2025
Company
Source: Medpace 10-Q for the quarter ended Sep 30, 2026, filed Oct 22, 2026
By product or service
Source: Medpace 10-Q for the quarter ended Sep 30, 2026, filed Oct 22, 2026
The bull case and the bear case
The bull case
- Revenue rose 20.0% in FY2025 to $2.5B, from $2.1B a year earlier. 10-K, FY2025
- Net income rose 11.6% in FY2025 to $451M, from $404M. 10-K, FY2025
- Operating cash flow rose 17.1% in FY2025 to $713M. 10-K, FY2025
- Diluted shares fell 7.8% in FY2025, so each share represents a larger slice of profit. 10-K, FY2025
The bear case
- Antiviral and Anti Infective revenue fell 13.8% in FY2025 to $135M. 10-K, FY2025
- The company's own risk factors are in Item 1A of its 10-K. Risks common in this industry include regulation; pricing and reimbursement; competition. 10-K, Item 1A
What optimists and skeptics tend to point to, each tied to a filing. Ticker Sage doesn't pick a side, and neither list is a reason to buy or sell.
What the company does
Medpace is in the life sciences tools & services industry, part of the health care sector. The SEC files it under Services-Commercial Physical & Biological Research.
The full description of Medpace's business is in Item 1 of its 10-K, linked below. This page shows its revenue by product or service.
Its fiscal year ends in December; the latest, FY2025, ended Dec 31, 2025.
Source: 10-K, Item 1 Business
Risks common in this industry
These are general risks for companies in the life sciences tools & services industry. They are not a summary of Medpace’s own risk factors; for those, read Item 1A of its latest 10-K, linked below.
- RegulationApprovals, safety rules and government oversight shape what it can sell and how.
- Pricing and reimbursementPayers, insurers and governments influence what it can charge.
- CompetitionNew treatments, generics and rival products can take share.
- LitigationProduct liability and other legal claims can lead to costs.
- SupplyManufacturing and supplier problems can interrupt products.
Source: 10-K, Item 1A Risk Factors (the company's own list, in the company's words)
Three years of key numbers
Every number links to its filing; hover for the XBRL tag. A dash means the number isn't cleanly available, and we don't estimate it.
| US$ | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $1.9B | $2.1B | $2.5B |
| Net income | $283M | $404M | $451M |
| Operating cash flow | $433M | $609M | $713M |
| Cash & equivalents (year end) | $245M | $669M | $497M |
| Diluted shares | 32M | 32M | 30M |
- Revenue: Total revenue for the fiscal year, as the company reports it on its income statement.
- Net income: Net income attributable to the company's shareholders, after all costs, interest and taxes.
- Operating cash flow: Cash the business brought in from its day-to-day operations during the year (cash flow statement).
- Cash & equivalents: Cash and short-term investments that count as cash equivalents on the balance sheet. Excludes longer-dated marketable securities.
- Diluted shares: Weighted average shares outstanding for the year, including the effect of options and stock awards.
Learn more: How to read an income statement · Earnings per share, basic and diluted · Free cash flow · How to read a balance sheet · Growth rate calculator · P/E calculator · Market cap calculator · Free cash flow calculator · Return on equity and assets calculator
Explainers for this page
- The cash flow statement
- Risk factors (Item 1A)
- Legal proceedings and loss contingencies
- Debt-to-equity ratio
- Market cap and enterprise value
- Contractual commitments
- Interest and taxes paid
Guides to terms this file uses, with real numbers from filings.
About these numbers
What we left out
- Total debt: the company's filing data doesn't carry a consistent debt total for the years shown, so it isn't shown.
Recent filings
| Form | Filed | Period |
|---|---|---|
| 10-Q | Oct 22, 2026 | Sep 30, 2026 |
| 10-Q | Jul 23, 2026 | Jun 30, 2026 |
| 10-Q | Apr 23, 2026 | Mar 31, 2026 |
| DEF 14A | Apr 1, 2026 | May 15, 2026 |
| 10-K | Feb 10, 2026 | Dec 31, 2025 |
What's in this filing
The quotes below come from Item 1 (Business) of the Form 10-K Medpace filed on Feb 10, 2026, its annual report for the fiscal year ended Dec 31, 2025.
The latest quarterly report in the table above is the Form 10-Q filed Oct 22, 2026 for the quarter ended Sep 30, 2026.
A 10-K has audited annual financial statements and the company's own description of its business and risks; a 10-Q has unaudited quarterly statements.
We are one of the world’s leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries.
Our mission is to accelerate the global development of safe and effective medical therapeutics.
Short excerpts quoted from the filing. The full document is on SEC.gov.
Learn more: 10-K vs. 10-Q vs. 8-K · Form 4 insider filings · Fiscal years and quarters
Common questions about Medpace
How does Medpace make money?
Medpace's revenue was $2.5B in fiscal 2025. By product or service in FY2025: Oncology (30%), Metabolic (29%), Other (16%) and Central Nervous System (10%), as shares of total revenue. Total revenue was $2.5B. Source: 10-K for fiscal 2025, filed Feb 10, 2026.
What was Medpace's revenue in fiscal 2025?
$2.5B of revenue for the fiscal year ended Dec 31, 2025, up 20.0% from $2.1B in fiscal 2024. Fiscal 2023 was $1.9B. Source: 10-K for fiscal 2025, filed Feb 10, 2026.
Is Medpace profitable?
Medpace reported net income of $451M for fiscal 2025, up 11.6% from $404M in fiscal 2024. That is a profit under US accounting rules (GAAP). In the quarter ended Sep 30, 2026, net income was $137M. The page's About these numbers section explains what is included. Source: 10-K for fiscal 2025, filed Feb 10, 2026.
What did Medpace report in its latest quarterly filing?
Revenue was $716M in the quarter ended Sep 30, 2026, up 8.5% from $660M a year earlier. Net income was $137M, up 23.7% from $111M. Source: 10-Q for the quarter ended Sep 30, 2026, filed Oct 22, 2026.
What are the main risks Medpace faces?
Medpace's own risk factors are in Item 1A of its 10-K for fiscal 2025, filed Feb 10, 2026. Risks that are common among companies in the life sciences tools & services industry include Regulation; pricing and reimbursement; competition; litigation; supply. The first: Approvals, safety rules and government oversight shape what it can sell and how. Source: 10-K, Item 1A Risk Factors.
Where do these Medpace numbers come from?
From Medpace's own SEC filings: the 10-K for fiscal 2025 (filed Feb 10, 2026) and the 10-Q for the quarter ended Sep 30, 2026 (filed Oct 22, 2026), read through the SEC's public XBRL data. Each number on this page links to its filing. Methodology explains how fiscal years and missing numbers are handled.
Tracked funds that report owning Medpace
- Renaissance Technologies: 452,428 shares, reported value $282.4M at Sep 30, 2026 (+8.9% in shares since the filing for Jun 30, 2026). Form 13F filed Nov 12, 2026.
- Baillie Gifford: 451,764 shares, reported value $282.0M at Sep 30, 2026 (−4.5% in shares since the filing for Jun 30, 2026). Form 13F filed Nov 9, 2026.
- Bridgewater Associates: 57,506 shares, reported value $35.9M at Sep 30, 2026 (+268.5% in shares since the filing for Jun 30, 2026). Form 13F filed Nov 16, 2026.
- Millennium Management: 38,775 shares, reported value $24.2M at Sep 30, 2026 (new in this filing). Form 13F filed Nov 16, 2026.
- Fundsmith: 25,940 shares, reported value $16.2M at Sep 30, 2026 (−50.5% in shares since the filing for Jun 30, 2026). Form 13F filed Nov 16, 2026.
- Two Sigma Investments: 22,429 shares, reported value $14.0M at Sep 30, 2026 (+130.3% in shares since the filing for Jun 30, 2026). Form 13F filed Nov 16, 2026.
- Point72 Asset Management: 15,812 shares, reported value $9.9M at Sep 30, 2026 (new in this filing). Form 13F filed Nov 16, 2026.
From each fund’s latest Form 13F, which is filed up to 45 days after quarter end and lists long positions in US-listed stocks only. A listing here is a fact about a filing, not a view on the stock. What a 13F does and doesn’t show.
Disclosures
- Editor holdings in MEDP
- The editor holds no position in Medpace (MEDP). As of Nov 11, 2026.
- Trading rule
- The editor does not buy or sell MEDP from 3 days before to 3 days after this page is published or substantively updated.
- Compensation
- Nobody paid for this page. No affiliate links on this page.
- Sources
- The company's SEC filings, linked next to each number or, for charts, in the source line under them.
- Last updated
- Nov 20, 2026
General education, the same for every reader. Not a recommendation to buy, sell or hold MEDP, and it doesn't consider your situation.
Compare with peers
| Company | Fiscal year | Revenue | Revenue growth | Net income |
|---|---|---|---|---|
| MedpaceMEDP | FY2025 | $2.5B | +20.0% | $451M |
| Thermo FisherTMO | FY2025 | $44.6B | +3.9% | $6.7B |
| DanaherDHR | FY2025 | $24.6B | +2.9% | $3.6B |
| Agilent TechnologiesA | FY2025 | $6.9B | +6.7% | $1.3B |
| WatersWAT | FY2025 | $3.2B | +7.0% | $643M |
Each row is that company’s latest fiscal year from its own 10-K, using its own revenue and net income lines. Fiscal years end in different months, and line definitions differ (banks, insurers and oil companies count revenue differently), so this is a rough side-by-side, not a like-for-like comparison.
More company files
- LLY Eli Lilly
- JNJ Johnson & Johnson
- ABBV AbbVie
- MRK Merck
- AMGN Amgen
- GILD Gilead
- PFE Pfizer
- BMY Bristol Myers Squibb
- VRTX Vertex Pharmaceuticals
- HCA HCA Healthcare
- REGN Regeneron Pharmaceuticals
- MRNA Moderna
- VEEV Veeva Systems
- IQV IQVIA
- ILMN Illumina
- BIIB Biogen
- MTD Mettler Toledo
- ZTS Zoetis
- INCY Incyte
- VTRS Viatris
- CRL Charles River Laboratories
- SOLV Solventum
- TECH Bio-Techne
- UHS Universal Health Services
- UTHR United Therapeutics
- THC Tenet Health
- ALNY Alnylam
- AAPL Apple
- MSFT Microsoft
- NVDA Nvidia
New to filings? Learn has explainers built on real filings and Tools has calculators. Methodology & Disclosures covers where every number comes from.